Voyager Therapeutics (NASDAQ:VYGR) Cut to Hold at StockNews.com

StockNews.com lowered shares of Voyager Therapeutics (NASDAQ:VYGR - Free Report) from a buy rating to a hold rating in a report released on Sunday.

A number of other equities research analysts have also recently issued reports on VYGR. Wedbush dropped their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, October 24th. Leerink Partnrs upgraded Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, October 16th. Finally, Leerink Partners started coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They set an "outperform" rating and a $15.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Voyager Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $17.43.

Voyager Therapeutics Price Performance

NASDAQ VYGR traded up $0.03 on Friday, hitting $7.13. 365,871 shares of the stock were exchanged, compared to its average volume of 682,543. The company has a market capitalization of $388.80 million, a PE ratio of 25.46 and a beta of 0.89. The business's fifty day moving average is $6.60 and its 200 day moving average is $7.54. Voyager Therapeutics has a 52 week low of $5.71 and a 52 week high of $11.72.

Insider Buying and Selling

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares of the company's stock, valued at $500,525.82. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.53% of the stock is currently owned by insiders.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Great Point Partners LLC acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth $12,668,000. Farallon Capital Management LLC grew its stake in Voyager Therapeutics by 77.4% during the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company's stock worth $21,339,000 after buying an additional 1,000,000 shares in the last quarter. Vanguard Group Inc. increased its holdings in Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company's stock valued at $30,087,000 after buying an additional 702,030 shares during the period. Armistice Capital LLC raised its position in shares of Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock valued at $41,132,000 after buying an additional 528,000 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Voyager Therapeutics by 32.4% during the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company's stock worth $8,063,000 after acquiring an additional 249,659 shares during the period. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.